Related Experiment Videos
Entecavir (Bristol-Myers Squibb).
1Novartis Research Institute, General Dermatology, Vienna, Austria. andreas.billich@pharma.novartis.com
Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
Summary
Entecavir is a potent antiviral drug developed for hepatitis B virus (HBV) infection. It inhibits viral DNA polymerase, showing high efficacy and low toxicity in clinical trials.
Area of Science:
- Virology
- Hepatology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection poses a significant global health challenge.
- Current treatments for HBV infection have limitations, necessitating the development of novel antiviral agents.
- Entecavir, a cyclopentyl guanosine analog, was initially investigated for herpes simplex virus infections.
Purpose of the Study:
- To evaluate the efficacy and safety of entecavir for the treatment of hepatitis B virus (HBV) infection.
- To characterize the mechanism of action of entecavir as a viral replication inhibitor.
Main Methods:
- Entecavir's antiviral activity was assessed by measuring its inhibitory concentration (ED50) against HBV.
- Cytotoxicity was evaluated by determining the 50% cytotoxic concentration (CC50).
- The mechanism of action was investigated through its effect on HBV DNA polymerase.
Main Results:
- Entecavir demonstrated potent inhibition of HBV replication with an ED50 of 3.0 nM, significantly lower than lamivudine (200 nM).
- The compound exhibited low toxicity, with a CC50 of 30,000 nM.
- Entecavir acts by inhibiting HBV DNA polymerase, with its triphosphate form being a potent inhibitor in preclinical models.
Conclusions:
- Entecavir is a highly potent and selective inhibitor of HBV replication.
- Its favorable efficacy and safety profile support its continued development for HBV treatment.
- Clinical trials are underway to further establish entecavir's therapeutic value in patients with HBV infection.